Type 2 Diabetes Patients With Renal Impairment

Summary

The purpose of the study is to evaluate the effect of kidney function on pharmacokinetics and pharmacodynamics of DWP16001 following single and multiple oral doses in type 2 diabetes patients with normal kidney function and renal impairment.

Timeline

Start

2020-01

Primary completion

2020-08

Completion

2020-10

Publications

• Jeong SI, Ban MS, Hwang JG, Park MK, Lim S, Kim S, Kwon SK, Kim Y, Cho JM, Na JJ, Huh W, Chung JY. The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium-glucose cotransporter-2 inhibitor, in type 2 diabetes. Diabetes Obes Metab. 2024 Jul;26(7):2588-2597. doi: 10.1111/dom.15573. Epub 2024 Apr 15.

Drugs

Indications